AgPlenus, a subsidiary of Evogene, to Present at the 2nd Annual AgChem & Technology Europe Conference

Boaz Inbal, VP R&D, will present AgPlenus’ unique approach for biology-driven discovery and introduce AgPlenus’ vision and pipeline

 Rehovot, Israel – November 19, 2018 – AgPlenus, a fully owned subsidiary of Evogene Ltd. (NASDAQ, TASE: EVGN), an innovative company aiming to discover, develop and bring to the market effective and safe agrochemical products utilizing proprietary computational predictive technologies, announces today that it will participate in the 2nd Annual AgChem & Technology Europe Conference.

Dr. Boaz Inbal, AgPlenus’ VP R&D, will present AgPlenus’ unique approach for biology-driven discovery and optimization of novel agrochemicals, addressing market challenges of increasing resistance and product safety requirements.

Dr. Inbal will be presenting at the 2nd annual AgChem & Technology Europe Conference taking place November 20th-21st, 2018 in London, UK. Dr. Inbal’s presentation is scheduled for Tuesday, November 20th at 13:55.

-xxx

 About AgPlenus Ltd.

AgPlenus, a fully owned subsidiary of Evogene Ltd. (NASDAQ, TASE: EVGN), aims to discover, develop and bring to the market effective and safe agrochemical products utilizing proprietary computational predictive technologies. The Company aims to develop agrochemicals: herbicides, insecticides, fungicides and crop enhancers. AgPlenus will continue ongoing collaborations with industry leaders such as BASF and ICL. For more information, please visit www.agplenus.com

About Evogene Ltd.:

Evogene (NASDAQ, TASE: EVGN) is a leading biotechnology company developing novel products for major life science markets through the use of a unique computational predictive biology (CPB) platform incorporating deep scientific understandings and advanced computational technologies.

Today, this platform is utilized by the Company to discover and develop innovative products in the following areas (via subsidiaries or divisions): ag-chemicals, ag-biologicals, seed traits, integrated castor oil ag-solutions and human microbiome based therapeutics. Each subsidiary or division establishes its product pipeline and go-to-market, as demonstrated in its collaborations with world-leading companies such as BASF, Corteva, Bayer and ICL. For more information, please visit www.evogene.com

Forward Looking Statements:

This press release contains “forward-looking statements” relating to future events. These statements may be identified by words such as “may”, “could”, “expects”, “intends”, “anticipates”, “plans”, “believes”, “scheduled”, “estimates” or words of similar meaning. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which beyond Evogene’s control, including, without limitation, those risk factors contained in Evogene’s reports filed with the appropriate securities authority. Evogene disclaims any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions.

Contact:

Nir Zalik

IR/PR Manager

E: IR@evogene.com

T: (+972)-8-931-1963

US Investor Relations

Vivian Cervantes

PCG Advisory

E: vivian@pcgadvisory.com

T: 646-863-6274

Back to Press releases